We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · June 04, 2021

Switching to Riociguat vs Maintenance Therapy With PDE-5 Inhibitors in Patients With Pulmonary Arterial Hypertension

The Lancet Respiratory Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Switching to Riociguat Versus Maintenance Therapy With Phosphodiesterase-5 Inhibitors in Patients With Pulmonary Arterial Hypertension (REPLACE): A Multicentre, Open-Label, Randomised Controlled Trial
Lancet Respir Med 2021 Mar 24;[EPub Ahead of Print], MM Hoeper, H Al-Hiti, RL Benza, SA Chang, PA Corris, JSR Gibbs, E Grünig, P Jansa, JR Klinger, D Langleben, VV McLaughlin, GMB Meyer, J Ota-Arakaki, AJ Peacock, T Pulido, S Rosenkranz, CD Vizza, A Vonk-Noordegraaf, RJ White, M Chang, F Kleinjung, C Meier, K Paraschin, HA Ghofrani, G Simonneau

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading